Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

29.58 0.14 +0.48%
Market cap
$167.8B
P/E
38.9×
Fwd P/E
12.2×
Dividend yield
5.81%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
41,358.00 42,822.00 42,898.00 46,924.00
Total non-current assets
159,773.00 164,795.00 165,263.00 161,807.00
Total Assets
201,131.00 207,618.00 208,160.00 208,731.00
Total current liabilities
32,646.00 34,348.00 36,984.00 36,596.00
Total non-current liabilities
82,992.00 82,866.00 84,399.00 79,039.00
Total liabilities
115,639.00 117,214.00 121,385.00 115,635.00
Common Equity (Total)
85,492.00 90,403.00 86,775.00 93,097.00
Shareholders Equity (Total)
85,492.00 90,404.00 86,775.00 93,096.00
Total Debt
63,194.00 64,455.00 64,795.00 61,712.00

Show all line items

In millions of $ except per-share values · columns are period end dates